Omega-3: Beyond the Fish Oil
Omega-3 fatty acids represent one of the most extensively researched nutrients in modern nutritional science. Decades of clinical trials and consistent findings across independent institutions have established a clear, well-replicated evidence base for EPA and DHA — the two long-chain omega-3 fatty acids most directly linked to human health. And yet a comprehensive global review published in December 2025, led by researchers from the University of East Anglia and the University of Southampton, reached an uncomfortable conclusion: 76% of the world's population is not consuming recommended levels of EPA and DHA.
That is three in four people falling short of one of the most robustly evidenced nutrients in existence.
(University of East Anglia / University of Southampton — Three-quarters of global population not getting enough Omega-3)
Why most people are deficient
The primary dietary sources of EPA and DHA are oily fish — salmon, mackerel, sardines, anchovies. The problem is twofold. First, most modern diets do not include these in meaningful quantities. Second, and less widely known, public health guidance in many countries recommends limiting oily fish consumption due to the accumulation of heavy metals — particularly mercury — in larger marine species. Eating enough oily fish to meet EPA and DHA requirements daily is not, for most people, a realistic or advisable strategy.
Plant-based sources provide a different form of omega-3 that the body converts to EPA and DHA only very inefficiently. For the majority of people, diet alone is not a reliable route to adequate levels.
The result is a chronic, largely invisible shortfall. Unlike acute nutrient deficiencies, low omega-3 status does not produce sudden or obvious symptoms. It contributes instead to a background of elevated inflammation, impaired cardiovascular function, and suboptimal cognitive performance that accumulates silently over time.
What the evidence shows
The cardiovascular evidence for EPA and DHA is among the most consistent in nutritional science. A meta-analysis of 38 randomised controlled trials conducted at Brigham and Women's Hospital, Harvard Medical School, found that higher EPA and DHA intake was associated with reduced risk of cardiovascular events, with particularly strong evidence for reductions in triglycerides, improvements in endothelial function, and anti-inflammatory effects. A systematic review cited in that analysis found that a daily intake of at least 250mg of EPA and DHA was associated with a statistically significant 35% reduction in the risk of sudden cardiac death.
DHA is also a primary building block of the brain — it is one of the most abundant fatty acids in brain tissue and plays a direct structural role in how neurons communicate. Clinical research has found associations between higher DHA levels and reduced cognitive decline, and between EPA and improvements in mood and inflammatory markers relevant to mental health.
More broadly, EPA and DHA produce signalling molecules that actively resolve inflammatory responses in the body. Chronic low-grade inflammation is increasingly understood as an underlying factor in conditions ranging from metabolic syndrome to autoimmune disease — which is why the anti-inflammatory properties of omega-3 have implications that extend well beyond cardiovascular health.
(Brigham and Women's Hospital / Harvard Medical School — Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis)
Why concentration and form matter
Most standard fish oil products on the market contain 30–50% EPA and DHA combined. A clinical study comparing omega-3 formulations at different concentration levels found that participants receiving higher concentration products — at 80% or above — achieved significantly higher EPA and DHA blood levels and greater reductions in triglycerides than those on lower concentration formulations, despite being administered the same absolute dose. Concentration is not a labelling detail. It determines how much active omega-3 actually reaches the bloodstream per capsule.
(ScienceDirect — The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters)
Molecular form matters for the same reason. Omega-3 in its natural triglyceride form is absorbed more efficiently than the ethyl ester form — a synthetic intermediate created during the concentration process — and is less dependent on dietary fat for absorption.
The evidence base for omega-3 is unusually strong for a nutritional supplement. But that evidence was built on specific doses, specific forms, and specific concentrations. A product delivering 30% EPA and DHA in ethyl ester form does not carry the findings of high-dose triglyceride trials with it. The clinical benefit follows the formulation — and formulation is precisely where most products on the market cut corners.
Dr. Jose Rokiski
5th June 2026